Global Cancer Therapies Industry

• Publication date: October 2011

This report analyzes the worldwide markets for Cancer Therapies in US$ Million by the following Product Segments: Immunotherapy, Targeted Therapy, Hormonal Therapy, and Chemotherapy. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets. The report profiles 152 ...

This report analyzes the worldwide markets for Cancer Therapies in US$ Million by the following Product Segments: Immunotherapy, Targeted Therapy, Hormonal Therapy, and Chemotherapy. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets. The report profiles 152 companies including many key and niche players such as Amgen, Inc., AstraZeneca PLC, Bayer Schering Pharma, Biogen Idec Inc., Bristol-Myers Squibb Company, Celgene Corporation, Cell Therapeutics, Inc., Cephalon, Inc., Chugai Pharmaceutical Co., Ltd., Eli Lilly and Company, Imclone Systems, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., Genzyme, GlaxoSmithKline, Janssen Biotech, Inc., Merck KGaA, Novartis AG, OSI Pharmaceuticals, Inc., Pfizer, Sanofi-Aventis, Seattle Genetics, Inc., and Takeda Pharmaceutical Company Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Global Biological Therapy Industry

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 3
Quantitative Techniques & Analytics 3
Product Definitions and Scope of Study 3
Immunotherapy 4
Targeted Therapy 4
Hormonal Therapy 4
Chemotherapy 4

2. INDUSTRY OVERVIEW 5
Cancer Therapies: An Outlook 5
US Retains Global Dominance 5
Immunotherapies Lead the Suite, Targeted Therapies to Claim
the Top Spot 5
Cancer Therapies: A Review 6
Enduring Success of Top Drug Makers Makes Oncology Area More
Endearing 7
Table 1: Select Leading Cancer Therapies Worldwide by
Revenues: 2006-2010 (includes corresponding Graph/Chart) 7
Monoclonal Antibodies Open Up a New Era in Cancer Treatment 8
Table 2: Leading Monoclonal Antibodies Worldwide by
Revenues: 2009 & 2010 8
Biotherapies to Drive Growth in Cancer Therapy Market 9
Biotech Cancer Therapies Yet to Overcome Teething Issues 9
Oncology Drugs - the Leader in the Global Pharma Pipeline 9
Table 3: Cancer Therapies Market: Number of
Approved/Marketed and Pipeline Drugs by Select Cancer Types
as of 2010 (includes corresponding Graph/Chart) 10
New Cancer Therapies Appear Over the Horizon 10
Late Stage Promising Drugs in Cancer Therapy 11
US Ahead in Approving Cancer Drugs 11
FDA-Approved Oncology Drugs in Recent Years (2008-2011) 12
New Cancer Drugs Approved by EMA in 2009 and 2010 13
Competition Set to Rise in Cancer Therapy 13
Table 4: Leading Companies in the Global Oncology Therapy
Market (2010): Percentage Breakdown of Revenues for Roche,
Novartis, Amgen, AstraZeneca, sanofi-aventis and Celgene
(includes corresponding Graph/Chart) 14
Competition Intensifies in the Cancer Biotherapy Segment 14

3. TRENDS AND ISSUES 15
Innovations in Cancer Drug Delivery: A Key Factor in Product
Differentiation 15
Follow-On Indications Flock Oncology Pipeline 15
Personalized Medicine: Gain in Importance 15
Combination Therapy: A Double Whammy Success 15
Patent Expiries of Branded Drugs to Trigger Generic Competition 16
Rising Investments Bring in New Troubles for Drug Makers 16
Emerging Challenges in Cancer Drug Development 16
Select Drugs Receiving Complete Response Letters from the
FDA in 2010 17
Drug Failures - Deterring Prospects of New Therapies 17
Failures in Phase III Clinical Trials of Oncology Drugs in 2010 18
Drug Withdrawals Hurt Pharma Companies 18

4. MARKET DRIVERS AND RESTRAINTS 19
Growth Drivers In a Capsule 19
Rise in Cancer Incidences & Access to Modern Therapeutics
Foster Growth 19
Demographics & Lifestyles Raise the Risk of Cancer 19
Cancer Prone Sites based on Age 20
Table 5: Population of People Aged More than 65 Years in
United States for the years 2000, 2010, and 2020 (includes
corresponding Graph/Chart) 20
Unmet Needs Leave Scope for Further Research and Development 20
Low Entry Barriers in Cancer Research Encourages
Breakthrough Developments 20
Increasing Investments by National Health Authorities 21
Efficiency & High Prices Magnetize Manufacturers 21
Supportive Cancer Drugs Contribute to Growth 21
Improved Screening, Diagnosis & Patient Survival Rates
Trigger Growth 21
Molecular Imaging of Cancer: Critical in Improving Patient
Outcomes 22
Innovations, Improvements, and Approvals Propel Growth 23
Growth Restraints 23
High Prices of Targeted Therapies Act as a Speed Breaker 23
Table 6: Estimated Average Monthly Cost of Select Leading
Cancer Drugs in the US as of 2008 24
Limited Tumor Specificity and Toxicity 24
Complicated Treatment Protocols: A Major Stumbling Block in
Patient Compliance 24
Reduced Smoking 25
Reimbursement and Coverage Remains a Major Challenge 25
Changes in Reimbursement Policies Influence Market Prospects 25
Multiple Drug Resistance 26
Stringent Regulations Delay Market Approval 26
Challenges Encountered in Clinical Trials 26
High Development Costs Retracts Manufacturers in Developing
Countries 27

5. TARGETED THERAPEUTICS 28
Current and Future Analysis 28
Targeted Therapy - An Overview 28
Targeted Therapy: The New Frontier of Cancer Treatment 28
List of Select Approved Targeted Therapy Drugs by Indication 29
Select Targeted Anti-Cancer Therapies in Late-Stage (Phase
III) Clinical Development 29
Table 7: Targeted Therapies Market Worldwide (2010):
Percentage Breakdown of Targeted Therapeutic Drugs under
Various Stages of Development (includes corresponding
Graph/Chart) 30

Table 8: Molecular Targeted Therapies Worldwide: Percentage
Breakdown of Molecular Targeted Therapies under Pipeline by
Drug Class as of 2010 (includes corresponding Graph/Chart) 31
Types of Targeted Therapy 31
Tyrosine Kinase Inhibitors 31
List of Approved Tyrosine Kinase Inhibitors 32
Angiogenesis Inhibitors 32
List of Approved Angiogenesis Inhibitors 32
Proteasome Inhibitors 32
Multi-Targeted Drugs 32
Select Approved Multi-Targeted Drugs in Targeted Cancer
Therapy 33
Gene Therapy 33

6. IMMUNOTHERAPY 34
Current and Future Analysis 34
Table 9: Global Market for Immunotherapy (2007 and 2012):
Percentage Breakdown of Revenues by Drug Class - Monoclonal
Antibodies, Biological Response Modifiers, Vaccines, and
Other Immunotherapy Products (includes corresponding
Graph/Chart) 34
Immunotherapy Treatment Strategies 35
Vaccination with Dendritic Cells Pulsed With Tumor Antigens 35
Gene Technique-Based Immunotherapy 35
Inhibiting Tumor-Induced Immunosuppression 35
Immunostimulants 35
Use of Monoclonal Antibodies 35
Immunotoxins 35
Radioimmunotherapy 35
T Cells based Therapy 35
Types of Cancer Immunotherapy Drugs 35
Monoclonal Antibodies 35
Select Immunotherapy-based Monoclonal Antibodies Approved
for Cancer Treatment 36
Vaccines - A Promising Future Area of Cancer Therapeutics 36
Therapeutic Cancer Vaccines: Harnessing the Immune System
to Fight Cancer 36
Cancer Vaccine Strategies 37
RNA-Loaded Dendritic Cells Cancer Vaccine: 37
Liposomal Vaccine: 37
Vaccine Targeting Pregnancy Hormone: 37
Viral Vector Vaccine: 37
Listeria-Based Vaccine: 37
Telomerase Targeting Vaccine: 37
Cancer Vaccine Makes Debut in the US, Finally 37
Approved Therapeutic Cancer Vaccines Worldwide 38
Cancer Vaccine Pipeline Shows Significant Promise 38
World Cancer Vaccine Pipeline as of 2011 39
Long-Drawn Journey to Success Offers New Lessons for Drug
Makers 39

7. HORMONE THERAPY 40
Current and Future Analysis 40
Hormonal Therapy - An Overview 40
Hormonal Therapy Strategies 40
Hormone Synthesis Inhibitors 40
Aromatase Inhibitors 41
GnRH Analogs 41
Hormone Receptor Antagonists 41
Selective Estrogen Receptor Modulators (SERMs) 41
Antiandrogens 41
Hormone Supplementation 41
Progestagens and Androgens 41
Estrogens 41
Somatostatin Analogs 41
Shifting Therapeutic Preferences 41
Table 10: Global Market for Antihormonal Therapy (2005 and
2014): Percentage Breakdown of Revenues by Drug Class - LHRH
Analogs, Aromatase Inhibitors, Anti-androgens,
Anti-estrogens, and Other Hormone Antagonists (includes
corresponding Graph/Chart) 42
Drug Classes in Hormone Therapy 42
Drugs Used in Hormone Therapy and Their Uses 42
Side-Effects Associated with the Use of Various Drugs in
Hormone Therapy 43

8. CHEMOTHERAPY 44
Current and Future Analysis 44
Chemotherapy - An Overview 44
The Chemotherapy Market Space - An Overview 45
Chemotherapy Market Cluttered with Numerous Players 45
Chemotherapy Drugs Require Careful Handling 46
Types of Chemotherapy 46
Adjuvant Chemotherapy 46
Combined Modality Chemotherapy 46
Neoadjuvant Chemotherapy 46
Palliative Chemotherapy 46
Chemotherapy Drug Classes 46
Nucleoside Analogues 46
Alkylating Agents 46
Antimetabolites 46
Nitrosoureas 46
Steroid hormones 46
Platinum Containing Compounds 46
Folate antagonists 46
Microtubule-targeting agents 46
Topoisomerase inhibitors 46
Risks Associated with Chemotherapy 47
When Chemotherapy Fails 47

9. AN OVERVIEW OF CANCERS 48
Cancer: A Major Health Crisis in the Modern World 48
Table 11: Cancer Causes in Developed and Developing Countries
(2010): Percentage Breakdown by Risk Factors - Diet or
Nutrition, Infections, Tobacco, and Other Factors (includes
corresponding Graph/Chart) 48
Types of Cancers 49
Prostate Cancer 49
Select FDA-Approved Prostate Cancer Drugs 49
Select Prostate Cancer Agents in Mid- & Late-Stage Clinical
Development 50
Table 12: Revenues of Select Leading Prostate Cancer Drugs:
2006-2010 (includes corresponding Graph/Chart) 50
Breast Cancer 51
Select FDA Approved Breast Cancer Drugs 51
Table 13: Breast Cancer Drug Pipeline: Number of Drugs by
Development Stage as of 2010 (includes corresponding
Graph/Chart) 52
Cervical Cancer 52
Colorectal Cancer 52
Select FDA-Approved Colorectal Cancer Drugs 53
Table 14: Colorectal Cancer Drug Pipeline: Number of Drugs
by Development Stage as of 2010 (includes corresponding
Graph/Chart) 53
Lung Cancer 54
Select FDA-Approved Non-Small Cell Lung Cancer Drugs 54
Table 15: Lung Cancer Drug Pipeline: Number of Drugs by
Development Stage as of 2010 (includes corresponding
Graph/Chart) 55
Renal Cancer 55
Select FDA-Approved Renal Cell Carcinoma Drugs 55
Skin Cancer 55
Table 16: Skin Cancer/Melanoma Drug Pipeline: Number of
Drugs by Development Stage as of 2010 (includes
corresponding Graph/Chart) 56
Pancreatic Cancer 56
Table 17: Pancreatic Cancer Drug Pipeline: Number of Drugs
by Development Stage as of 2010 (includes corresponding
Graph/Chart) 56
Non-Hodgkin’s Lymphoma 57
Leukemia 57
Bladder Cancer 57
Table 18: Bladder Cancer Drug Pipeline: Number of Drugs by
Development Stage as of 2010 (includes corresponding
Graph/Chart) 57
Endometrial Cancer 57

10. WORLD CANCER STATISTICS 58
Cancer Incidence - Statistics on New Cases 58
Table 19: Global Cancer Incidence by Region: 2009 (includes
corresponding Graph/Chart) 58
Table 20: Global Cancer Incidence by Income Group: 2009
(includes corresponding Graph/Chart) 59
Table 21: Cancer Incidence in Upper Middle Income Countries
by Site: 2009 (includes corresponding Graph/Chart) 59
Table 22: Cancer Incidence in Lower Middle Income Countries
by Site: 2009 (includes corresponding Graph/Chart) 60
Table 23: Cancer Incidence in High Income Countries by Site:
2009 (includes corresponding Graph/Chart) 61

11. DRUG APPROVALS AND CLINICAL TRIALS 62
Merck Receives Approval for EMEND® IV in Canada 62
Sun Pharma Receives FDA Approval for Docefrez 62
Amgen Secures FDA Approval for Denosumab 62
Eisai Receives FDA Approval for Halaven 62
Dendreon Corporation Secures FDA Approval for Provenge 63
GlaxoSmithKline Secures Accelerated Approval from FDA for TYKERB 63
Roche Receives European Commission Approval for Herceptin in
Metastatic Gastric Cancer Treatment 63
Gloucester Pharmaceuticals Receives FDA Approval for Istodax 63
YM BioSciences Gains Marketing Approval for Nimotuzumab in
Mexico 64
Bristol-Myers and ImClone Receives FDA Approval for Erbitux
Labeling Revisions 64
Abraxis Receives Approval for Abraxane in Quebec, Canada 64
Genentech Receives FDA Approval for Avastin 64
ABRAXANE Gains Marketing Approval in Korea, Australia and
Other Countries 65
GlaxoSmithKline's Cervarix Finds Place in UK National
Immunization Programme 65
Biogen Idec and Elan Commence Clinical Trial of TYSABRI 66
Calistoga Pharmaceuticals Starts Phase I Clinical Trial of
CAL-101 66
Progen Pharmaceuticals Continues Phase 1 Development of PG-11047 66
GlaxoSmithKline Receives Conditional EU Approval for
Marketing Lapatinib 66
Roche’s Xeloda Gains EU Approval for Use in Colorectal Cancer
Treatment 66
Genentech Secures FDA Approval for Avastin 67
EU Approves Four Biosimilar Versions of Neupogen 67
Russia Approves Oncophage for Kidney Cancer Treatment 67
Eisai to Start Clinical Testing of MORAb-028 67
Threshold Pharmaceuticals Starts Phase I/II Clinical Trials
of TH-302 67
AVEO Commences Phase 1b Clinical Study of AV-951 and FOLFOX6 68
GSK’s Tykerb Receives USFDA Approval 68
Seattle Genetics Initiates Phase 1b Clinical Trials of SGN-40
with Gemzar and Rituxan 68
S*Bio Initiates Phase I Clinical Trials of SB1518 68
Merck Serono Initiates Phase III Trials of Cladribine 68
BioCurex Receives Patent for RECAF Technology Applications 69
Chidamide/HBI-8000 Completes Phase I Clinical Trials in China 69
AVEO Initiates Phase I Trials of AV 299 69
Exelixis Completes Phase I Trials of XL765 69
Infinity Pharmaceuticals Starts Phase I Clinical Trial of
IPI-926 69
Cell Genesys Terminates its VITAL-1 Phase 3 Trial of GVAX 70
GTx Completes Phase II Clinical Trials of Ostarine 70
Imclone Awaits Approval for Erbitux from US Medicine Regulator 70
Kuhnil and Daiichi Sankyo Initiate Phase II Clinical Trial of
Nimotuzumab 70
Peplin Starts Phase III Clinical Trials of PEP005 Gel 70
ERBITUX Receives Marketing Approval in Japan 71
Progenics Starts Phase I Clinical Study of PSMA ADC 71
FDA Awards Orphan Drug Designation for the Use of Stem Cell
Technology in Bone Marrow Transplantations 71
Roche, OSI and Chugai Receive Approval for Tarceva in Japan 71
Eisai Receives FDA Approval for ONTAK® 72
Genmab Terminates the Development of HuMax-CD4 72
Teva Pharmaceutical Acquires EU Authorization to Market
Neutropenia Drug 72
Novartis’ Everolimus Awaits Approvals from US FDA,
Swissmedic, and EMEA 72
Abraxis BioScience, AstraZeneca, and NCCN to Conduct Anti-
cancer Drug Studies 72
Sanofi-Aventis Receives Japanese Approval for Taxotere®
Injection 73
Roche’s Avastin Bags European Approval for Renal Cancer Treatment 73
Roche Announces European Approval of Herceptin 73
GSK’s Hycamtin Obtains FDA Approval 73
Avastin Receives European Approval for Breast Cancer Treatment 74
Roche’s Tarceva Obtains European Approval 74
Roche’s NeoRecormon Gains European Approval 74
Northwest Biotherapeutics’ DCVax-Brain Gains Swiss Approval 74
Alfacell’s ONCONASE Receives Orphan Drug Designation from US 74
Cougar Biotechnology Commences Phase II Trial of CB7630 75
Lorus Therapeutics Receives Orphan Drug Designation for its
LOR-2040 75
Merck Serono Receives EU Approval for mCRC Treatment With
Erbitux 75
MGI PHARMA and HELSINN Receive FDA Approval For Aloxi 75
FDA Grants Approval for Sutent, a Kidney and Gastrointestinal
Cancer Drug 75
Wyeth Pharmaceuticals’ TORISEL Receives FDA Approval 76
Dabur Pharma Acquires FDA Approval for Paclitaxel Injection 76
EUSA’s CAPHOSOL Finds Application in Treating Oral Mucositis 76
European Commission Approves Amgen’s Vectibix for Metastatic
Colorectal Cancer 76
GPC Biotech Starts Phase 2 Trials of Satraplatin plus with
Tarceva 77
FDA Approves Vectibix as Treatment for Metastatic Colorectal
Cancer 77
FDA Approves IND Indication for CYT-500 of Cytogen 77
FDA Clears Rituxan for New Indications 77
Epeius Receives BFAD Approval for Expanded Access Program for
Rexin- G 78
BioMedicines Initiates Phase 1b Study of Biomed 101 78
Avastin Obtains FDA Approval for Treating Recurrent
Colorectal Cancer 79
Genentech’s Herceptin Gains FDA Nod for Treating Early stage
Cancer after Surgery 79
Epeius Starts Phase I and II Trials of the New Tri-Rex
Vaccination Protocol 79
Sonus Begins Phase 1 Clinical Trial of TOCOSOL® Camptothecin 79
Dynavax Begins Phase 1 Clinical Trial of TLR9 agonist Combined
with Chemotherapy Regimen 79
Morphotek’s MORAb-009 Receives Orphan Drug Designation 80
Morphotek’s MORAb-003 Receives Orphan Drug Status from the US
FDA 80
Morphotek Grants FDA Approval of the IND for MORAb-009 80
MannKind Receives IND Clearance for MKC1106-PP Immunotherapy 81
Pharmexa Initiates Phase II trials of GV 1001 81
Wyeth Pharmaceuticals Declares Discontinuation of Phase III
Clinical Trials for Temsirolimus 81
OXiGENE Announces Clinical Trials of CA4P 82
Glaxo SmithKline’s Hycamtin Gains FDA Approval for Treating
Cervical Cancer 82
Cell Genesys Announces the Initiation of Amplified Phase I
Trial of CG0070 82
Genentech’s Avastin Receives FDA Approval for Lung Cancer
Treatment 82
Vorinostat Acquires FDA Approval for Skin Cancer Treatment 83
Callisto Launches the First Clinical Trial of Landmark
Discovery, L-Annamycin for ALL 83
Shanghai Sunway Biotech’s H101 Receives Marketing Approval in
China 84
Northwest Biotherapeutics Gains Patent for CXCR4 84
Biocon’s Cancer Drug Initiates Phase II Trials 84

12. NEW DRUG DEVELOPMENTS AND LAUNCHES 85
Dr Reddy's Laboratories Introduces Peg-Grafeel Injection in
India 85
Sanofi-Aventis Introduces Jevtana (cabazitaxel) Injection in
the US 85
Natco Pharma Introduces Anastrazole for Breast Cancer in US 85
Dr Reddy's Laboratories Introduces Anastrazole Tablets in US 85
Zynx Health Introduces Zynx OncologyCare 85
Ferring Pharmaceuticals Introduces FIRMAGON® in Europe 86
GSK Launches Cervarix in Singapore 86
Abeome Launches New Stem Cell Monoclonal Antibody 86
Dabur Pharma Launches a New Drug Delivery System, Nanoxel 87
Epeius Biotechnologies Develops New Targeted Anti-Cancer Drugs 87
Monash University Scientists Develop siRNA for Cancer Treatment 87
Cytogen Introduces SOLTAMOX™, the First Hormonal Breast
Cancer Therapy 87

13. RECENT INDUSTRY ACTIVITY 88
BioLineRx Acquires License Rights of BL-7030 from Algen 88
Glenmark Establishes New Manufacturing Plant in Argentina 88
Centella Therapeutics Signs Licensing Agreement with Auckland
UniServices 88
Cephalon Enters a Definitive Merger Agreement with Gemin X 88
IRX Therapeutics Enters a New Research Collaboration 89
RXi Pharmaceuticals Acquires Apthera 89
Gilead Sciences to Enter into Collaboration with Yale School
of Medicine for Cancer Therapies 89
Sage Bionetworks Forms Alliance with AstraZeneca 89
Amgen Acquires BioVex Group 90
AREVA Inks Cooperative Research Agreement with INSERM 90
Dendreon Secures FDA Approval for New Jersey Manufacturing
Facility 90
Celgene Acquires Abraxis BioScience 90
HUYA Partners with Quintiles to Co-Develop HBI-8000 Cancer
drug (US/China) 91
China PharmaHub Signs Agreement with Global Player in
Precision Glass Technology 91
Immunotope Partners with Midatech Group to Form Syntara 91
ChromoCure Acquires GRG 91
Qatar National Cancer Society and SAH Global Sign MoU 92
Neogenix Gains FDA Orphan Drug Designation for Ensituximab 92
ImmunoGen Gains Orphan Drug Status for Lorvotuzumab Mertansine 92
Syngene International Enters Into Agreement with Endo
Pharmaceuticals 92
Immunovaccine and Oncothyreon Ink Research Agreement 92
OncoGenex Inks Licensing Agreement with Teva Pharmaceutical 93
NanoCarrier Enter into Comprehensive Joint Research Agreement
with MEDINET 93
VaxOnco Acquires Intellectual Property Rights for Onyvax-P 93
Novation Pharmaceuticals and Cancer Therapeutics Enter into
Collaboration 93
Cancer Therapeutics Signs Letter of Intent with NanoTherapies 94
sanofi-aventis Acquires BiPar Sciences 94
IBt Bebig, Rusnanotech and Santis Form Joint Venture for
Cancer Treatment 94
Roche Acquires Genentech 94
AstraZeneca Enters into Collaboration with Merck 95
Cytopia Merges with YM BioSciences 95
Aveo Pharmaceuticals and Biogen Idec Sign Definitive Agreement 95
Opsona Therapeutics Inks Research and Collaboration Agreement
with CSL 95
Micromet Signs Agreement with Lonza 96
Clavis Pharma Enters Into Agreement with Clovis Oncology 96
Abraxis Takes Over Platco and Shimoda 96
WEHI Collaborates with Abbott and Genentech 97
Novartis Inks a Production Deal with Lonza 97
Roche Takes Over UK-Based Biotech Company, Piramed 97
Pfizer Acquires Encysive 98
Eden Biodesign Inks a Marketing Services Deal with Human
Genome Sciences 98
FivePrime Join Hands with Pfizer for Cancer and Diabetes
Research 98
Sanofi-Aventis and Dyax Ink Two Antibody Pacts 99
Pfizer and AVANT Ink a Global Licensing Agreement for CDX-110 99
Takeda Inks an Exclusive Partnership Agreement with Amgen 100
Genentech and Roche Ink a Licensing Agreement with Glycart 100
Bristol-Myers Squibb Acquires Kosan Biosciences 100
Nabi Biopharmaceuticals Collaborates with NIAID 100
Pfizer to Acquire Serenex 101
Morphotek Signs an Agreement with Pivotal BioSciences 101
GE Healthcare Inks a Three-Year Agreement with Eli Lilly 101
ArQule Signs Two Agreements with Daiichi Sankyo 101
Circadian Completely Acquires Vegenics Limited 102
Lpath Inks an Accord with Merck Serono 102
Topex Expands its Distribution Deal with Therapy Remarketing 102
Unibioscreen Inks a Partnership Agreement with Drais
Pharmaceuticals 102
Avant Immunotherapeutics Becomes Celldex Therapeutics 102
Abraxis Enters into Definitive License Agreements with
ProMetic Life Sciences 103
Biovest International to Receive US$1.6 Million Funding for
Biomedical Research 103
Access Completes the Acquisition of Somanta 103
Clinical Data Inks an Agreement to Take Over Avalon
Pharmaceuticals 103
EUSA Pharma Acquires Cytogen Corporation 104
Oncologic Merges with Triton BioSystems 104
Eli Lilly Takes Over ImClone Systems 104
CEL-SCI Establishes a New Manufacturing Unit 105
ZaBeCor Establishes Biothorpe Pharmaceuticals, a New Subsidiary 105
Takara Bio Signs a Research Agreement with a Chinese University 105
Shanghai Roche Expands its MabThera Marketing Activities 105
Merck Completes the Acquisition of Majority Stake in Serono 105
Merck Enters into Licensing and Collaboration Agreement With
Idera 106
Sanofi-Aventis Inks a Global Licensing Deal with Oxford
BioMedica 106
WEHI to Collaborate with Genentech and Roche 106
AstraZeneca Acquires MedImmune 106
Antisoma Enters into a Global Accord with Novartis 107
Sanofi-Aventis and Astellas Pharma to Restructure their JV
Operations in Japan 107
Biomira Amends its Agreements with Merck 107
AstraZeneca Takes Over Canadian Biologics Plant 107
Pfizer Acquires Coley Pharmaceutical Group 108
Abraxis Takes Over Watson’s Manufacturing Facility 108
Abraxis Takes Over Pfizer’s Cruce Davila Manufacturing Facility 108
Bristol-Myers Squibb Takes Over Adnexus Therapeutics 109
Merck Partners with a Florida-based Research Center 109
Organon Partners with Medarex 109
Genzyme Acquires Bioenvision 109
Genentech Inks a Deal with Seattle Genetics 109
TopoTarget Takes Over Apoxis 109
Roche Acquires CuraGen’s Subsidiary 110
GPC Biotech Inks an Agreement with Yakult 110
MediGene Acquires Avidex 110
Sanofi-Aventis Inks an Agreement with Taiho 110
Biogen Inks Merger Agreement with Conforma 111
Roche Signs a Merger Agreement with Ventana 111
Roche Takes Over THP to Enhance Its Therapeutic Antibody Profile 111
ImClone Systems and Merck Revise ERBITUX Agreement 111
GSK Invests €500 Million in France 112
Amgen Takes Over Avidia 112
Moores Cancer Center Collaborates with Medarex 112
ADITUS Medical Forms an Alliance with IGEA 112
Callisto Opens Site For Phase-II Clinical Trials of Atiprimod 113
XOMA Inks an Agreement with Attenuon 113
AstraZeneca Joins Schering to Develop a Novel Breast Cancer Drug 113
Nventa to Procure Hiltonol from Oncovir Incorporated 113
MaxCyte and Medinet Sign an Agreement for Immuno- Cell Therapy 114
Receptor Acquires Cancer Vaccine ‘G17DT’ from Aphton 114
Enzon Collaborates with Santaris for Joint Development of
Novel RNA Antagonists 115
Epeius Receives Funding from Lazarex for Rexin-G™ Trials 115
Callisto Inks a Deal with M.D. Anderson Cancer Center 115
AstraZeneca Inks an Agreement with Abraxis BioScience 116
diaDexus and BVF Establish CFD Therapeutics 116
Merck Acquires US Rights for Liposome Vaccine 116
Genentech Enters Into Alliance with Inotek 117
AstraZeneca Takes Over KuDOS Pharmaceuticals 117
Genzyme Acquires AnorMED 117
Genentech Collaborates with Accelerate Brain Cancer Cure 118
Sonus and Schering Enter into a Global Licensing Agreement 118
Abgenix Inks Merger Agreement with Amgen 118
AstraZeneca and Astex Enter into an Alliance 119
Pfizer Inks Global License Pact with Coley Pharmaceutical Group 119
Genzyme Takes Over ILEX Oncology 120
Genentech and CGI Enter into an Exclusive Agreement 120

14. FOCUS ON SELECT PLAYERS 121
Amgen, Inc. (USA) 121
Amgen’s Oncology Pipeline As of 2011 121
AstraZeneca PLC (UK) 122
AstraZeneca’s Cancer Drugs Under Pipeline as of 2011 122
Bayer Schering Pharma (Germany) 123
Bayer’s Oncology Pipeline (As of 2011) 124
Biogen Idec Inc (USA) 124
Bristol-Myers Squibb Company (USA) 124
Celgene Corporation (USA) 125
Celgene’s Oncology Drug Pipeline (As of 2011) 125
Cell Therapeutics, Inc. (USA) 125
Cell Therapeutics’ Oncology Pipeline (As of 2011) 126
Cephalon, Inc. (USA) 126
Cephalon’s Oncology Pipeline (As of 2011) 127
Chugai Pharmaceutical Co., Ltd. (Japan) 127
Chugai’s Oncology Drug Pipeline (As of 2011) 128
Eli Lilly and Company (USA) 128
Lilly’s Oncology Drug Pipeline as of 2011 129
Imclone Systems, Inc (USA) 130
F. Hoffmann-La Roche Ltd (Switzerland) 130
Select Mid- and Late- Stage Compounds in Roche’s Oncology
Pipeline 131
Genentech, Inc. (USA) 132
Genzyme (USA) 132
Genzymes’ Oncology Drug Pipeline as of 2011 133
GlaxoSmithKline (UK) 133
GlaxoSmithKline’s Oncology Pipeline (As of 2011) 134
Janssen Biotech, Inc (USA) 134
Merck KGaA (Germany) 135
Merck Serono’s Oncology Pipeline (As of 2011) 135
Novartis AG (Switzerland) 136
Novartis’ Oncology Drug Pipeline (As of 2011) 136
OSI Pharmaceuticals, Inc. (USA) 137
OSI Pharmaceuticals’ Oncology Pipeline Status (As of 2011) 137
Pfizer (USA) 137
Pfizer’s Oncology Drug Pipeline (As of 2011) 138
Sanofi-Aventis (France) 138
Oncology Drug Pipeline of sanofi-aventis as of 2011 139
Seattle Genetics, Inc. (USA) 139
Seattle’s Cancer Therapy Pipeline as of 2011 140
Takeda Pharmaceutical Company Limited (Japan) 140
Takeda’s Oncology Pipeline (As of 2011) 141

15. GLOBAL MARKET PERSPECTIVE 142
Table 24: Global Recent Past, Current & Future Analysis for
Cancer Therapies by Geographic Region - US, Japan, Europe and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) 142

Table 25: Global Historic Review for Cancer Therapies by
Geographic Region - US, Japan, Europe and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 143

Table 26: Global 15-Year Perspective for Cancer Therapies by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Japan, Europe and Rest of World for Years 2003, 2010 &
2017 (includes corresponding Graph/Chart) 144
Analytics by Segment 145
Table 27: Global Recent Past, Current & Future Analysis for
Immunotherapy by Geographic Region - US, Japan, Europe and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) 145

Table 28: Global Historic Review for Immunotherapy by
Geographic Region - US, Japan, Europe and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 146

Table 29: Global 15-Year Perspective for Immunotherapy by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Japan, Europe and Rest of World for Years 2003, 2010 &
2017 (includes corresponding Graph/Chart) 147

Table 30: Global Recent Past, Current & Future Analysis for
Targeted Therapy by Geographic Region - US, Japan, Europe and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) 148

Table 31: Global Historic Review for Targeted Therapy by
Geographic Region - US, Japan, Europe and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 149

Table 32: Global 15-Year Perspective for Targeted Therapy by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Japan, Europe and Rest of World for Years 2003, 2010 &
2017 (includes corresponding Graph/Chart) 150

Table 33: Global Recent Past, Current & Future Analysis for
Hormone Therapy by Geographic Region - US, Japan, Europe and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) 151

Table 34: Global Historic Review for Hormone Therapy by
Geographic Region - US, Japan, Europe and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 152

Table 35: Global 15-Year Perspective for Hormone Therapy by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Japan, Europe and Rest of World for Years 2003, 2010 &
2017 (includes corresponding Graph/Chart) 153

Table 36: Global Recent Past, Current & Future Analysis for
Chemotherapy by Geographic Region - US, Japan, Europe and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) 154

Table 37: Global Historic Review for Chemotherapy by
Geographic Region - US, Japan, Europe and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 155

Table 38: Global 15-Year Perspective for Chemotherapy by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Japan, Europe and Rest of World for Years 2003, 2010 &
2017 (includes corresponding Graph/Chart) 156

16. THE UNITED STATES 157
A.Market Analysis 157
Current and Future Analysis 157
Table 39: Sales of Select Leading Cancer Drugs in the US
(2009 & 2010) (includes corresponding Graph/Chart) 157
Recession Hits the Pharma Market, Oncology Area too Succumbs 158
Medicare Restructures its Coverage for Chemotherapy 158
Personalized Care for Cancer Treatment in US 158
Drugs in Development in the US - A Recent Past Scenario 159
Chemotherapy Drugs Undergoing Trials for Breast Cancer
Treatment in United States (as of 2007) 159
Hormonal Therapy Drugs Undergoing Trials for Breast Cancer
Treatment in United States (as of 2007) 159
Targeted Therapy Drugs Undergoing Trials for Breast Cancer
Treatment in United States (as of 2007) 160
Statistical Findings 161
Table 40: US Market for Hospital Cancer Therapies (2004
and 2010): Percentage Breakdown of Revenues by Treatment
Type - Surgery, Chemotherapy Drugs, Radiation Therapy,
Biotechnology-Based Drugs, and Others (includes
corresponding Graph/Chart) 161

Table 41: US Demand for Chemotherapy Drugs (2004 and 2010):
Percentage Breakdown of Revenues by Drug Class - Alkylating
Agents & Related, Antimetabolites & Related, Mitotic
Inhibitors, and Others (includes corresponding
Graph/Chart) 161

Table 42: US Market for Multiple Myeloma Therapeutics
(2009): Percentage Breakdown of Revenues by Company -
Celgene Corporation, Millennium Pharmaceuticals and Others
(includes corresponding Graph/Chart) 162

Table 43: US Market for Breast Cancer Therapeutics (2010):
Percentage Breakdown of Revenues by Segment: Targeted
Therapeutics, Cytotoxic Therapeutics, and Hormonal
Therapeutics, and (includes corresponding Graph/Chart) 162
US Cancer Statistics 163
Table 44: New Cancer Cases in the US by Affected Site: 2009
(includes corresponding Graph/Chart) 163

Table 45: New Cancer Cases in Males in US by Leading Site:
2009 (includes corresponding Graph/Chart) 165

Table 46: New Cancer Cases in Females in US by Leading
Site: 2009 (includes corresponding Graph/Chart) 166
Cancer Mortality Statistics 167
Table 47: Cancer Related Deaths in the US By Affected Site:
2009 (includes corresponding Graph/Chart) 167

Table 48: Cancer Related Deaths in Males in US by Leading
Site: 2009 (includes corresponding Graph/Chart) 169

Table 49: Cancer Related Deaths in Females in US by Leading
Site: 2009 (includes corresponding Graph/Chart) 170
New Drug Approvals 170
New Drug Launches 172
Strategic Corporate Developments 173
Focus on Select Major Players 177
B.Market Analytics 188
Table 50: The US Recent Past, Current & Future Analysis for
Cancer Therapies by Segment - Immunotherapy, Targeted
Therapy, Hormone Therapy, and Chemotherapy Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) 188

Table 51: The US Historic Review for Cancer Therapies by
Segment - Immunotherapy, Targeted Therapy, Hormone Therapy,
and Chemotherapy Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2003 through 2008
(includes corresponding Graph/Chart) 189

Table 52: The US 15-Year Perspective for Cancer Therapies
by Segment - Percentage Breakdown of Dollar Sales for
Immunotherapy, Targeted Therapy, Hormone Therapy, and
Chemotherapy for Years 2003, 2010 & 2017 (includes
corresponding Graph/Chart) 190

17. JAPAN 191
A.Market Analysis 191
Current and Future Analysis 191
Focus on Select Major Players 191
B.Market Analytics 194
Table 53: Japanese Recent Past, Current & Future Analysis
for Cancer Therapies by Segment - Immunotherapy, Targeted
Therapy, Hormone Therapy, and Chemotherapy Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) 194

Table 54: Japanese Historic Review for Cancer Therapies by
Segment - Immunotherapy, Targeted Therapy, Hormone Therapy,
and Chemotherapy Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2003 through 2008
(includes corresponding Graph/Chart) 195

Table 55: Japanese 15-Year Perspective for Cancer Therapies
by Segment - Percentage Breakdown of Dollar Sales for
Immunotherapy, Targeted Therapy, Hormone Therapy, and
Chemotherapy for Years 2003, 2010 & 2017 (includes
corresponding Graph/Chart) 196

18. EUROPE 197
A.Market Analysis 197
Current and Future Analysis 197
Regional Perspective 197
Advancements in Breast Cancer Treatment in Europe 198
New Formulations that are Under Clinical Trials 198
Drugs Undergoing Trials for Bladder Cancer Treatment in
Europe As of 2006 198
European Cancer Statistics 199
Table 56: Cancer Incidence in Europe by Site (2009)
(includes corresponding Graph/Chart) 200
New Drug Approval 201
New Drug Launch 201
Strategic Corporate Developments 201
Focus on Select Major Players 204
B.Market Analytics 213
Table 57: European Recent Past, Current & Future Analysis
for Cancer Therapies by Segment - Immunotherapy, Targeted
Therapy, Hormone Therapy, and Chemotherapy Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) 213

Table 58: European Historic Review for Cancer Therapies by
Segment - Immunotherapy, Targeted Therapy, Hormone Therapy,
and Chemotherapy Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2003 through 2008
(includes corresponding Graph/Chart) 214

Table 59: European 15-Year Perspective for Cancer Therapies
by Segment - Percentage Breakdown of Dollar Sales for
Immunotherapy, Targeted Therapy, Hormone Therapy, and
Chemotherapy for Years 2003, 2010 & 2017 (includes
corresponding Graph/Chart) 215

19. REST OF WORLD 216
A.Market Analysis 216
Current and Future Analysis 216
Regional Market Overview 216
Canada 216
Table 60: Estimated New Cancer Cases by Type/ Site Among
Canadian Men: 2010 (includes corresponding Graph/Chart) 216

Table 61: Estimated New Cancer Cases by Type/Site Among
Canadian Women: 2010 (includes corresponding Graph/Chart) 217

Table 62: Estimated Cancer Deaths by Type/Site Among
Canadian Men: 2010 (includes corresponding Graph/Chart) 217

Table 63: Estimated Cancer Deaths by Type/Site Among
Canadian Women: 2010 (includes corresponding Graph/Chart) 218
Asia 218
Cancer Statistics in Asia-Pacific 218
Table 64: Cancer Incidence in Asia-Oceania by Site: 2009
(includes corresponding Graph/Chart) 219
Australia 219
India 220
Korea 220
Malaysia 220
Latin America 221
Brazil 221
Mexico 221
Argentina 221
New Drug Approvals 221
New Drug Launches 222
Strategic Corporate Developments 223
B.Market Analytics 226
Table 65: Rest of World Recent Past, Current & Future
Analysis for Cancer Therapies by Segment - Immunotherapy,
Targeted Therapy, Hormone Therapy, and Chemotherapy Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) 226

Table 66: Rest of World Historic Review for Cancer Therapies
by Segment - Immunotherapy, Targeted Therapy, Hormone
Therapy, and Chemotherapy Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart) 227

Table 67: Rest of World 15-Year Perspective for Cancer
Therapies by Segment - Percentage Breakdown of Dollar Sales
for Immunotherapy, Targeted Therapy, Hormone Therapy, and
Chemotherapy for Years 2003, 2010 & 2017 (includes
corresponding Graph/Chart) 228


COMPETITIVE LANDSCAPE

Total Companies Profiled: 152 (including Divisions/Subsidiaries - 168)

------------------------------------------
Region/Country Players
------------------------------------------
The United States 96
Canada 11
Japan 8
Europe 34
France 6
Germany 4
The United Kingdom 7
Spain 3
Rest of Europe 14
Asia-Pacific (Excluding Japan) 14
Middle-East 5
------------------------------------------